SynderminTM is a low molecular-weight tripeptide derived from FGF-1 (fibroblast growth factor -1) that is involved in various cellular processes, including angiogenesis, keratinocyte organization, and wound healing.
The proliferation of cultured human keratinocyte cell line, HaCaT.
Syndermin treatment promoted the proliferation of HaCaT in a dose-dependent manner.
The activation of ERK and Akt in Fibroblasts.
Treatment of fibroblasts with Syndermin dose-dependently induced the activation of ERK1/2 and Akt, intracellular signaling molecules.
Promotion of neo-angiogenesis in vitro
Syndermin treatment significantly increased tubular formation of human umbilical vein endothelial cells in vitro.